This might explain why many studies regarding how pharmacogenetic (PGx) variants affect anti-VEGF drug response in exudative/wet AMD patients have reported results with moderate/high rates of heterogeneity [30,31,32]. The gene discussed is VEGFA; the disease is age-related macular degeneration.